Firms:Dibbsbarker (Regeneus Ltd)
Deal: Biotechnology company Regeneus’ listing on the Australian Stock Exchange (ASX)
Area: Equity Capital Markets
Value: The company’s IPO raised $10.5 million at $0.25 per share, which valued the company at $45.9 million upon listing
Key players: The DibbsBarker team was led by commercial partners Geoff Cairns and Lis Boyce (pictured)
Deal significance:This is the first listing of a biotechnology company on the ASX since 2011 Regeneus, which was founded in 2007, isa Sydney-based regenerative medicine company. The funds raised by the IPO will bolster the company’s research and development efforts and assist in the commercialisation of new technologies and therapies.